Alkermes plc.
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
About Alkermes
Pharmaceutical Preparations, SIC 2834
Alkermes plc is a biopharmaceutical company focusing on treatments for neurological and psychiatric conditions. Its proprietary commercial portfolio includes Aristada and Aristada Initio for schizophrenia, Lybalvi for schizophrenia and bipolar I disorder, Vivitrol for alcohol and opioid dependence, and Lumryz for narcolepsy. Additionally, the company licenses proprietary formulations to corporate partners, including Janssen for antipsychotics and Biogen for multiple sclerosis. Its products serve adult and pediatric patients with chronic diseases, as well as certified healthcare professionals and pharmacies.
Headquartered in Ireland, Alkermes operates a corporate office and research facility in Massachusetts, alongside a manufacturing site in Wilmington, Ohio. While the company commercializes its proprietary drugs in the United States, its licensed products are distributed globally through partner networks across the European Union and other international regions.
Summary of the business section of Alkermes's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alkermes plc.
- Headquarters
- Dublin 4, L2
- Address
- Connaught House, 1 Burlington Road 00000
- Phone
- 00-353-1-772-8000
- Employees
- 2,050, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ALKS
- Exchange
- Nasdaq
- IPO date
- Jul 16, 1991
- Shares outstanding
- 168M, Jul 23, 2026
- Public float
- $4.66B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, May 15, 2000
- SEC CIK
- 1520262
- CUSIP
- G01767105
- ISIN
- USG017671052
- EIN
- 98-1007018
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Blair Curtis Jackson | President & CEO, Alkermes plc, Director | 241,308 |
| Richard F. Pops | Director and CEO, Alkermes plc | 1,439,970 |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 223,422 |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 |
| Christian Todd Nichols | SVP, Chief Commercial Officer | 102,857 |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 11,109 |
| Joshua Reed | SVP, Chief Financial Officer | – |
| Iain Michael Brown | SVP, Chief Financial Officer | 148,196 |
| Anne Clem Whitaker | Director | – |
| nancy lynn snyderman MD | Director | 64,126 |
| Christopher I. Wright | Director | 25,680 |
| Frank Anders Wilson | Director | 35,751 |
| Shane Cooke | Director | 106,679 |
| Cato T. Laurencin | Director | 33,769 |
| Brian P. McKeon | Director | 48,536 |
| Richard Gaynor | Director | 37,226 |
| Nancy Lurker | Director | 19,697 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Richard F. Pops | $7.92M | $12.59M | $3.54M | $143 | $125 |
| FY2024 Richard F. Pops | $10.13M | $14.63M | $3.90M | $147 | $93 |
| FY2023 Richard F. Pops | $9.44M | $8.98M | $4.03M | $141 | $94 |
| FY2022 Richard F. Pops | $10.31M | $8.32M | $4.16M | $131 | $90 |
| FY2021 Richard F. Pops | $8.85M | $11.23M | $2.94M | $117 | $100 |
| FY2020 Richard F. Pops | $8.04M | $6.88M | $2.88M | $98 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 20, 2026, we had approximately 2,050 full time employees, of which approximately 1,950 were based in the U.S.”
Corporate history
Events identified from SEC filings